Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960282 · ClinicalTrials.gov registry record
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
A clinical trial, sponsored by University of Southern California.
- Terminated
- Registry status
- 21
- Enrollment target
NCT02960282 is a clinical trial that was terminated before completion, run by University of Southern California. The registered enrollment target is 21 participants.
The verdict
NCT02960282 was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- 21 participants
- Enrollment target
Study Summary
This research trial studies the gut microbiome in fecal samples from patients with cancer that has spread to other parts of the body who are undergoing chemotherapy or immunotherapy. Studying samples of feces from patients with metastatic cancer in the laboratory may help doctors learn if the make-up of the gut microbiome has a positive or negative influence to a patient's response to chemotherapy or immunotherapy.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2022-04-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960282
The ClinicalTrials.gov registry entry for NCT02960282 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT02960282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02960282 about?
NCT02960282 is a clinical study titled "Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy". This research trial studies the gut microbiome in fecal samples from patients with cancer that has spread to other parts of the body who are undergoing chemotherapy or immunotherapy. Studying samples of feces from patients with metastatic cancer in the laboratory may help doctors learn if the make-u...
What is the current status of trial NCT02960282?
This trial is currently terminated. The enrollment target is 21 participants. The study started on 2016-10-20. Estimated completion is 2022-04-13.
What interventions are being tested in trial NCT02960282?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02960282?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.